Semax

It's not a Western fiction — Semax has been a registered pharmaceutical in Russia since the 1990s, with real human studies behind that approval. But those studies are old, methodologically limited by today's standards, and have never been independently confirmed by a randomized, blinded Western trial — worth knowing before assuming "approved in Russia" carries the same evidentiary weight as an FDA approval.

What it is

Semax is a synthetic heptapeptide derived from ACTH(4-10), developed at Russia's Institute of Molecular Genetics, working through BDNF/NGF-related neurotrophic pathways rather than the classic hormonal effects of ACTH itself.

The Russian trial evidence

The anchor human study is Gusev, Skvortsova, Miasoedov et al., comparing 30 acute hemispheric ischemic stroke patients given Semax alongside standard therapy against 80 patients on conventional therapy alone, reporting faster neurological recovery in the Semax group (Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova, 1997;97(6):26-34, PMID 11517472). This is a real, decades-old trial by the design standards of its era — open-label rather than blinded, and never independently replicated in a Western randomized trial.

Regulatory status

Semax is registered as a pharmaceutical in Russia (since the 1990s) and Ukraine, for indications including ischemic stroke recovery, cognitive impairment and optic nerve atrophy. It has not been reviewed or approved by the FDA or EMA. It is also one of six peptides that FDA's Pharmacy Compounding Advisory Committee recommended, at its 23-24 July 2026 meeting, for Category 1/503A bulk-list eligibility in the US — see BPC-157's legal status page for how that same review process works. A recommendation is not an approval.

The evidence-quality gap

Selank, a related Russian peptide with a different, tuftsin-derived mechanism, is sometimes marketed alongside Semax; its sourcing looked thinner in our research and it isn't covered as its own page here.